An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer-Reference-Cited by-同舟云学术

An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Cremophor EL-Based Paclitaxel for Recurrent or Metastatic HER2-Negative Breast Cancer

Published:2017-07-15 Issue:3 Volume:49 Page:569-577
ISSN:1598-2998
Container-title:Cancer Research and Treatment
language:en
Short-container-title:Cancer Res Treat

Author:

Park In Hae,Sohn Joo Hyuk,Kim Sung Bae,Lee Keun Seok,Chung Joo Seop,Lee Soo Hyeon,Kim Tae You,Jung Kyung Hae,Cho Eun Kyung,Kim Yang Soo,Song Hong Suk,Seo Jae Hong,Ryoo Hun Mo,Lee Sun Ah,Yoon So Young,Kim Chul Soo,Kim Yong Tai,Kim Si Young,Jin Mi Ryung,Ro Jungsil

Funder

Samyang Biopharmaceuticals

Publisher

Korean Cancer Association

Subject

Cancer Research,Oncology

Link

http://www.e-crt.org/upload/pdf/crt-2016-289.pdf

Reference22 articles.

1. Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer

2. Use and abuse of taxanes in the management of metastatic breast cancer

3. Synthesis and evaluation of some water-soluble prodrugs and derivatives of taxol with antitumor activity